Haemonetics Corporation $HAE Shares Sold by William Blair Investment Management LLC

William Blair Investment Management LLC lowered its holdings in Haemonetics Corporation (NYSE:HAE) by 34.0% during the fourth quarter, HoldingsChannel reports. The fund owned 314,654 shares of the medical instruments supplier’s stock after selling 162,056 shares during the period. William Blair Investment Management LLC’s holdings in Haemonetics were worth $25,220,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the business. EverSource Wealth Advisors LLC increased its holdings in shares of Haemonetics by 366.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,709 shares of the medical instruments supplier’s stock valued at $137,000 after acquiring an additional 1,343 shares during the last quarter. Legato Capital Management LLC purchased a new position in shares of Haemonetics in the 4th quarter valued at about $1,057,000. Global Retirement Partners LLC purchased a new position in shares of Haemonetics in the 4th quarter valued at about $270,000. Leonteq Securities AG purchased a new position in shares of Haemonetics in the 4th quarter valued at about $30,000. Finally, Covestor Ltd increased its holdings in shares of Haemonetics by 184.9% in the 4th quarter. Covestor Ltd now owns 1,997 shares of the medical instruments supplier’s stock valued at $160,000 after acquiring an additional 1,296 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Citigroup reiterated an “outperform” rating on shares of Haemonetics in a report on Tuesday, May 12th. BTIG Research reiterated a “buy” rating and issued a $88.00 price objective on shares of Haemonetics in a report on Friday, February 6th. Barrington Research dropped their price objective on Haemonetics from $94.00 to $89.00 and set an “outperform” rating on the stock in a report on Tuesday, May 12th. Bank of America upgraded Haemonetics from a “neutral” rating to a “buy” rating and increased their price objective for the company from $72.00 to $80.00 in a report on Friday. Finally, Wall Street Zen upgraded Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $77.11.

Haemonetics Trading Down 0.0%

NYSE:HAE opened at $65.48 on Tuesday. The stock’s 50 day moving average price is $58.35 and its 200 day moving average price is $67.32. The company has a market capitalization of $2.98 billion, a PE ratio of 32.42, a P/E/G ratio of 1.32 and a beta of 0.53. The company has a quick ratio of 1.87, a current ratio of 2.95 and a debt-to-equity ratio of 1.53. Haemonetics Corporation has a 52-week low of $47.31 and a 52-week high of $87.32.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.01. The firm had revenue of $346.35 million for the quarter, compared to the consensus estimate of $336.83 million. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The firm’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the business posted $1.24 EPS. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. On average, research analysts anticipate that Haemonetics Corporation will post 5.23 EPS for the current year.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.